Does BALOXAVIR MARBOXIL Cause Product packaging quantity issue? 24 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 24 reports of Product packaging quantity issue have been filed in association with BALOXAVIR MARBOXIL (Xofluza). This represents 1.2% of all adverse event reports for BALOXAVIR MARBOXIL.
24
Reports of Product packaging quantity issue with BALOXAVIR MARBOXIL
1.2%
of all BALOXAVIR MARBOXIL reports
0
Deaths
0
Hospitalizations
How Dangerous Is Product packaging quantity issue From BALOXAVIR MARBOXIL?
Of the 24 reports.
Is Product packaging quantity issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BALOXAVIR MARBOXIL. However, 24 reports have been filed with the FAERS database.
What Other Side Effects Does BALOXAVIR MARBOXIL Cause?
No adverse event (511)
Off label use (409)
Intentional product use issue (282)
Diarrhoea (120)
Pneumonia (104)
Vomiting (104)
Drug ineffective (79)
Nausea (64)
Rash (55)
Colitis ischaemic (54)
What Other Drugs Cause Product packaging quantity issue?
LEUPROLIDE (523)
ALBUTEROL (431)
BUDESONIDE\FORMOTEROL (301)
FENTANYL (286)
BUPRENORPHINE (225)
CYCLOSPORINE (206)
ESTRADIOL (201)
BIMATOPROST (177)
RIVAROXABAN (174)
EXENATIDE (154)
Which BALOXAVIR MARBOXIL Alternatives Have Lower Product packaging quantity issue Risk?
BALOXAVIR MARBOXIL vs BALSALAZIDE
BALOXAVIR MARBOXIL vs BAMLANIVIMAB
BALOXAVIR MARBOXIL vs BAMLANIVIMAB\ETESEVIMAB
BALOXAVIR MARBOXIL vs BARACLUDE
BALOXAVIR MARBOXIL vs BARICITINIB